Genzyme's Manufacturing Problems

Genzyme looks increasingly vulnerable after the temporary closure of its Allston manufacturing facility resulted in shortages of one of its primary products, Cerezyme. Analysts remain divided on the long-term consequences, but there's no denying the the gaffes have created an opening for medicines from competitors Shire and Protalix.

In a town hall-style teleconference held August 26, Genzyme Corp.'s long-time CEO Henri Termeer admitted that the shutdown of its Allston Landing, MA-based manufacturing facility because of viral contamination earlier this summer resulted in "many, big expensive lessons." We are only beginning to know just how expensive the tutorial could be.

In early August, the company revealed 2009 sales of its blockbuster Gaucher disease drug imiglucerase (Cerezyme) would be reduced from...

More from Leadership

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Rising Leaders 2025: Regeneron’s Karen Rodriguez Lorenc On Not Believing In Failure

 
• By 

Karen Rodriguez Lorenc has overseen linvoseltamab's development and subsequent approval in Europe, now waiting for its US fate, she talked to In Vivo about how patient-centric drug development philosophy is core to her leadership, and why she doesn't believe in failure.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

More from In Vivo